Zacks Investment Research downgraded shares of CONCORD MED-ADR (CCM) from OUTPERFORM to NEUTRAL on January 20, 2015, with a target price of $8.20.
Concord Medical Services Holdings Limited operates a large network of radiotherapy and diagnostic imaging centers in China. Most of the centers in their network are established through long-term lease and management services arrangements entered into with their hospital partners. Under these arrangements, Concord Medical receives a contracted percentage of each center's revenue net of specified operating expenses. Each center is located on the premises of their hospital partners and is typically equipped with a primary unit of advanced radiotherapy or diagnostic imaging equipment, such as a linear accelerator, head gamma knife system, body gamma knife system, PET-CT scanner or MRI scanner.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CONCORD MED-ADR (CCM),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment